Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

356 - Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Junichi Hasegawa

Citation

Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431

Authors

J. Hasegawa1, T. Kato2, J. Nishimura3, S. Yoshioka4, S. Noura5, Y. Kagawa6, M. Yasui3, M. Ikenaga7, K. Murata6, T. Hata8, C. Matsuda8, T. Mizushima8, H. Yamamoto8, Y. Doki8, M. Mori8

Author affiliations

  • 1 Surgery, Osaka Rosai Hospital, 591-8025 - Sakai/JP
  • 2 Surgery, National Hospital Organization, Osaka National Hospital, Osaka/JP
  • 3 Gastroenterological Surgery, Osaka International Cancer Institute, Osaka/JP
  • 4 Surgery, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya/JP
  • 5 Surgery, Toyonaka Municipal Hospital, Toyonaka/JP
  • 6 Surgery, Kansai Rosai Hospital, Amagasaki/JP
  • 7 Surgery, Higashiosaka City Medical Center, Higashiosaka/JP
  • 8 Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita/JP
More

Resources

Abstract 356

Background

The standard strategy for locally advanced rectal cancer (LARC) is chemoradiotherapy followed by total mesorectal excision (TME) in Western countries and TME followed by adjuvant chemotherapy (CTx), without preoperative treatment in Japan.

Methods

This phase II trial evaluated the efficacy of a preoperative capecitabine plus oxaliplatin (CAPOX) CTx regimen without radiation therapy for patients with LARC. The primary endpoint was 2-year disease-free survival (DFS).

Results

The trial enrolled 45 patients from 9 institutions between 2012 and 2014. The mean age was 63.5 (29–74) years; 31 patients were male. Most patients (n = 41) received preoperative CTx, and the completion rate was 95.2%. R0 resection after CTx was performed in 41 patients. The pathological complete response (pCR) rate was 7.3% (3/41). After surgery, 35 patients (85.3%) received adjuvant CTx, and 22 of 35 completed the protocol treatment. The follow-up period ranged from 0.71 to 4.68 years (median 2.86 years). There was recurrence in 13 of 40 patients who underwent R0 resection, and the 2-year DFS rate and overall survival rate were 71.6% and 92.7%, respectively.

Conclusions

Here we report the completion rates for neoadjuvant CTx and adjuvant CTx, the pCR rate, and the mid-term prognosis. The results indicate that CAPOX followed by TME may be a feasible treatment strategy for locally advanced rectal cancer.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Clinical Study Group of Osaka University (CSGO) Colorectal Group.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.